Koppert W
Klinik für Anästhesiologie, Universitätsklinikum, Erlangen.
Schmerz. 2005 Oct;19(5):386-90, 392-4. doi: 10.1007/s00482-005-0424-9.
Opioids are frequently used for the treatment of moderate to severe acute and chronic pain. However, clinical evidence suggests that opioids can elicit increased sensitivity to noxious stimuli suggesting that administration of opioids can activate both, pain inhibitory and pain facilitatory systems. Acute receptor desensitization via uncoupling of the receptor from G proteins, upregulation of the cAMP pathway, activation of the N-methyl-D-aspartate (NMDA) receptor system and descending facilitation have been proposed as potential mechanisms underlying opioid-induced hyperalgesia. The tolerance results from a pain sensitization process more than from a decrease in the opioid effectiveness. Opioid-induced hyperalgesia and tolerance are observed both in animal and human experimental models. Brief exposures to mu-receptor agonists induce long-lasting hyperalgesic effects for days. Furthermore, the prolonged use of opioids in patients often requires increasing doses and may be accompanied by the development of abnormal pain. Successful strategies that may decrease or prevent opioid-induced hyperalgesia include the concomitant administration of drugs such as NMDA antagonists, alpha(2)-agonists, or nonsteroidal anti-inflammatory drugs (NSAID), opioid rotation, or combinations of opioids with different receptor selectivity.
阿片类药物常用于治疗中度至重度急性和慢性疼痛。然而,临床证据表明,阿片类药物可引发对伤害性刺激的敏感性增加,这表明阿片类药物的使用可激活疼痛抑制系统和疼痛易化系统。通过受体与G蛋白解偶联、cAMP途径上调、N-甲基-D-天冬氨酸(NMDA)受体系统激活以及下行易化作用导致的急性受体脱敏,已被提出作为阿片类药物诱导痛觉过敏的潜在机制。耐受性源于疼痛敏化过程,而非阿片类药物效力的降低。在动物和人类实验模型中均观察到阿片类药物诱导的痛觉过敏和耐受性。短暂暴露于μ受体激动剂会诱导持续数天的长期痛觉过敏效应。此外,患者长期使用阿片类药物通常需要增加剂量,并且可能伴有异常疼痛的发生。可能减少或预防阿片类药物诱导痛觉过敏的成功策略包括联合使用NMDA拮抗剂、α₂激动剂或非甾体抗炎药(NSAID)等药物、阿片类药物轮换,或使用具有不同受体选择性的阿片类药物组合。